ArticleUnited European gastroenterology journal2018
The impact of a history of cancer on pancreatic ductal adenocarcinoma survival.
Article in United European gastroenterology journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Clinical characterization and prognostic modeling of bladder cancer patients with a history of prior tumors: a SEER database analysis.Translational cancer research · 2025Article
- Prognostic impact of the presence or absence of prior cancer in patients with cancer using cure models: A population-based study.Cancer science · 2023Article
- Survival of cancer survivors with a new pancreatic cancer diagnosis.Cancer medicine · 2023Article
- Effect of prior malignancy on the prognosis of gastric cancer and somatic mutation.World journal of clinical cases · 2022Article
- Development and validation of a competing risk model for second primary pancreatic ductal adenocarcinoma: A population-based study.Frontiers in surgery · 2022Article
- The Impact of a History of Different Other Cancers on the Long-Term Outcomes of Patients with Intrahepatic Cholangiocarcinoma: A Population-Based Analysis.BioMed research international · 2022Article
- Clinical features of patients with pancreatic ductal adenocarcinoma with a history of other primary malignancies: A retrospective analysis.Molecular and clinical oncology · 2021Article
- The impact of a prior malignancy on outcomes in gastric cancer patients.Cancer medicine · 2021Article
- Oxytocin and oxytocin receptor alterations, decreased survival, and increased chemoresistance in patients with pancreatic cancer.Hepatobiliary & pancreatic diseases international : HBPD INT · 2020Article
- Impact of Prior Cancer on the Prognosis of Patients With Laryngeal Cancer: A Population-Based Study Using the Surveillance, Epidemiology, and End Results Database.Frontiers in oncology · 2020Article
- Article
- Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC).International journal of medical sciences · 2020Article
- The effects of a prior malignancy on the survival of patients with ovarian cancer: a population-based study.Journal of Cancer · 2020Article
- Natural History of Pancreatic Ductal Adenocarcinoma Diagnosed During Observation of Other Organ Cancers.The American journal of case reports · 2019Article
- Impact of prior cancer on outcomes in nasopharyngeal carcinoma.Annals of translational medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivePrevious studies indicated cancer survivors had a higher risk of developing subsequent pancreatic ductal adenocarcinoma. However, the influence of prior cancer on survival outcomes of current pancreatic cancer remains unclear.
methodsEligible populations were selected from the Surveillance, Epidemiology, and End Results programs from 2000 to 2012. We adopted Kaplan-Meier curves and Cox analysis to compare survival differences between patients with and without prior cancer.
resultsOverall, 67,555 pancreatic cancer patients, including 5582 (8.26%) with and 61,973 (91.74%) without prior cancer, were included. The most common types of prior cancers were prostate, breast, and colorectal cancers. The median time from diagnosis of an initial malignancy to subsequent pancreatic cancer was 59.8 months. Patients with a prior cancer had higher overall one-year and three-year survival rates compared with those without a prior cancer. Multivariable Cox analysis demonstrated that a history of prior malignancy could independently predict the better overall survival outcome of pancreatic cancer (HR = 0.92, 95% CI, 0.89-0.94,
conclusionsA history of cancer did not contribute to a poor survival outcome for patients with pancreatic cancer. More prospective trials might be warranted to validate our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.